Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Covalon TechnologiesCVALF +8.14%77 Price-to-Tangible-Book is 3.06 as of Sep. 06, 2026. GuruFocus rates CVALF with a GF Score™ of 77/100 and a GF Value™ of $1.57 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 701 Medical Devices & Instruments companies, Covalon Technologies ranks worse than 54.49% on this metric.
The historical rank and industry rank for Covalon Technologies's Price-to-Tangible-Book or its related term are showing as below:
CVALF'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.62 Med: 2.57 Max: 18.52
Current: 2.99
During the past 13 years, Covalon Technologies's highest Price to Tangible Book Ratio was 18.52. The lowest was 1.62. And the median was 2.57.
CVALF's Price-to-Tangible-Book is ranked worse than 54.49% of 701
companies
in the Medical Devices & Instruments industry
Industry Median: 2.62
vs CVALF: 2.99
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Covalon Technologies Price-to-Tangible-Book Related Terms
Covalon Technologies Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for Covalon Technologies's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CVALF vs ISRG, BDX, RMD: Price-to-Tangible-Book Comparison
For the Medical Instruments & Supplies subindustry, Covalon Technologies's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Covalon Technologies Price-to-Tangible-Book vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Covalon Technologies's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Covalon Technologies's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Covalon Technologies (CVALF) has a Price-to-Tangible-Book of 3.06 as of Sep. 06, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Covalon Technologies and its competitors. According to the industry distribution chart, Covalon Technologies ranks #382 out of 701 companies in the Medical Devices & Instruments industry, placing it in the top 54.5%.
Is Covalon Technologies' Price-to-Tangible-Book too high?
Covalon Technologies' current Price-to-Tangible-Book is 3.06. The Medical Devices & Instruments industry median Price-to-Tangible-Book is 2.62. Covalon Technologies' value of 3.06 is 16.8% above this industry median. Based on the distribution chart, Covalon Technologies ranks #382 out of 701 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Covalon Technologies has a GF Score™ of 77/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Covalon Technologies' Price-to-Tangible-Book compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Covalon Technologies ranks #382 out of 701 companies for Price-to-Tangible-Book. This places Covalon Technologies in the lower half of its industry. The industry median Price-to-Tangible-Book is 2.62. Covalon Technologies' value of 3.06 is 16.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Medical Devices & Instruments company?
The median Price-to-Tangible-Book among Medical Devices & Instruments companies is 2.62, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Covalon Technologies's current Price-to-Tangible-Book of 3.06 is 16.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Covalon Technologies and its competitors. For the Medical Devices & Instruments industry, the median Price-to-Tangible-Book is 2.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Covalon Technologies's current Price-to-Tangible-Book is 3.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Covalon Technologies stock overvalued right now?
Based on GuruFocus' analysis, Covalon Technologies (CVALF) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.57, compared to a current price of $2.39 — trading 52.2% above its estimated fair value. The current Price-to-Tangible-Book is 3.06 and 16.8% above the Medical Devices & Instruments industry median of 2.62. Covalon Technologies' overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For Covalon Technologies (CVALF), the current Price-to-Tangible-Book is 3.06 as of Sep. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Covalon Technologies (CVALF) Overvalued in 2026?
Based on GuruFocus' analysis, Covalon Technologies stock appears to be overvalued.
The current stock price of $2.39 is trading 52.2% above its estimated GF Value™ of $1.57.
GuruFocus considers Covalon Technologies to be Significantly Overvalued.
Key valuation signals for CVALF:
Price-to-Tangible-Book: 3.06
GF Value™: $1.57 vs. price of $2.39 (52.2% above fair value)
Industry Position: 16.8% above the Medical Devices & Instruments median (#382 of 701)
No single metric tells the full story. See the CVALF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Covalon Technologies Ltd is engaged in the business of researching, developing, manufacturing, and marketing patent-protected medical products that improve patient outcomes in the areas of infection management, wound care, and surgical procedures. The company generates revenue through development contracts, licensing agreements, distribution contracts, and sales. Its products include IV dressings, surgical site protection products, vascular access protection products, and others, and its solutions include primary dressing cover, vascular access technologies, advanced wound care, sensitive skin solutions, custom medical coatings, and patient resource support.
77GF Score
Get the complete analysis for CVALF
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CVALF has been successfully added to your 
